Perfluoro-[1,2-13C2] octanoic acid (M2PFOA)

You cannot taste, see, or smell them, but the industrial compounds known as PFAS are present in the blood of nearly everyone tested, and this urine test estimates your exposure to one of the most studied of them. Knowing your level matters because these chemicals leave the body slowly, over years rather than days.

This is a newer, research-grade measurement without agreed clinical cutoffs. It is best used to see where you stand and to watch your trend over time, especially if you suspect a contaminated water supply or a workplace source.

What This Test Actually Measures

The analyte at the center of this test is PFOA (perfluorooctanoic acid), a member of the family called per- and polyfluoroalkyl substances, or PFAS. The chemical name on the label, perfluoro-[1,2-13C2] octanoic acid, refers to a carbon-tagged version of PFOA that the lab uses as a reference standard to accurately count how much PFOA is in your urine sample.

PFOA is not made by any organ or cell in your body. It is a manufactured chemical used for decades in things like water-repellent coatings and non-stick cookware, and it reaches people mainly through drinking water and food. A result here reflects how much of this outside chemical your body is carrying and clearing, not any internal biological process.

One caveat shapes everything that follows. Most of the strongest human research on PFOA and health has measured it in blood (serum), not urine. Urine reflects what your kidneys are actively removing, which works reasonably well for PFOA but less well for longer-lived PFAS, so blood remains the more established way to gauge total body burden.

Immune Response and Vaccine Protection

The clearest human signal linking PFOA to a health effect involves the immune system. In a study of 101 healthy one-year-old children, those in the highest fifth of blood PFOA had markedly weaker antibody responses to routine vaccines than those in the lowest fifth, with differences of roughly 53 to 86 percent for antibodies against Haemophilus influenzae type b, tetanus, and diphtheria.

That same study estimated the blood levels where the effect began to appear at about 12.2, 16.9, and 16.2 micrograms per liter (a unit for very small concentrations) for the three vaccines. These figures come from blood measurements in young children, not urine PFOA in adults, so they describe the biology of the chemical rather than a threshold you should apply to your own urine result.

Kidney and Testicular Cancer

Among hard clinical outcomes, kidney cancer shows the most consistent link to PFOA. In a community of 32,254 adults living near a chemical plant, people in the highest quarter of estimated blood PFOA had about 58 percent higher kidney cancer risk than the lowest quarter, and a pooled analysis found roughly twice the risk of one kidney cancer type across a range of rising blood levels. In the same high-exposure population, testicular cancer risk in the top exposure quarter was about three times that of the lowest.

These findings are important but come with limits. They rely on blood measurements or modeled blood levels in a heavily exposed community, not on urine PFOA, and in general-population studies the overall associations are often weaker or appear only in specific subgroups, such as kidney cancer in women. Treat this as evidence that the chemical matters, not as a diagnosis your urine number can deliver.

Cholesterol, Liver, and Pregnancy

Higher blood PFOA has been tied to higher total and non-HDL cholesterol and to modest shifts in liver enzymes and markers in adults. These are blood-based associations, and their size is generally small.

During pregnancy, PFAS exposure has been linked to adverse fetal growth and birth outcomes, and to higher markers of oxidative stress and inflammation even at background exposure levels. Broader reviews connect the wider PFAS class to lower birth weight, developmental concerns, thyroid changes, and kidney effects, while noting the human evidence is not yet definitive.

Making Sense of the Contradictory Findings

Some results seem to point the wrong way. Higher PFOA tracks with higher cholesterol, yet a meta-analysis that included two Swedish cohorts found people with high PFOA had a modestly lower, not higher, cardiovascular disease risk, and higher PFOA was linked to lower short-term prostate cancer risk. This is not a good-number or bad-number marker in the usual sense. Because PFOA is cleared by the kidneys, illness that changes kidney handling, along with reverse causation in short follow-up, can distort these snapshots. The most defensible reading is that this is an exposure marker: a higher level means more of an unwanted chemical is in you, and the disease links are still being worked out rather than settled.

Why a Single Urine Reading Can Fool You

Urine is an imperfect window for legacy PFAS like PFOA, and a single result can mislead. In the U.S. general population, PFAS were often undetectable in urine even when blood clearly showed exposure, with about 67.5 percent of people having no detectable PFAS in urine at all. Longer-chain PFAS in particular are hard to catch in urine because so little is excreted that way.

• Kidney function: reduced kidney function, especially with protein in the urine, changes how much PFOA is filtered and reabsorbed, which can raise or lower a urine reading without changing your true exposure.
• Sex-related differences: urine and blood PFOA correlate strongly in men but weakly in women, likely because menstruation, pregnancy, and breastfeeding provide additional routes of elimination.
• How the sample is scaled: results are reported both per liter of urine and adjusted for creatinine (a waste product used to correct for how dilute the urine is), and these two numbers can differ.
• Low background levels: at ordinary exposure, PFOA may sit near the limit of what the assay can detect, making small differences unreliable.

Tracking Your Trend Over Time

Because this is an exploratory marker without standardized cutoffs, a single value tells you less than a trajectory does. PFOA leaves the body slowly, with an estimated half-life of roughly two to three years, so a level today reflects both recent intake and what has accumulated over years. That slow turnover is exactly why a baseline now, then repeat testing, lets you see whether your exposure is falling after you change something.

A practical rhythm: establish a baseline, retest in 6 to 12 months if you have removed a suspected source such as contaminated water, and check periodically thereafter. Because levels decline over years rather than weeks, do not expect a dramatic drop between closely spaced tests. Pairing a urine result with a blood PFAS measurement gives a fuller picture, since blood is the more established gauge of total body burden.

What to Do With an Unexpected Result

If your level is higher than you expected, the first move is to hunt for the source rather than to chase a number down. Investigate your drinking water, particularly private wells or municipal supplies near industrial sites, airfields, or firefighting-foam use, and consider dietary and occupational exposures. A confirming blood PFAS panel helps, since urine can understate long-chain PFAS.

Given the links to kidney and liver biology, it is reasonable to look at companion markers over time, including kidney filtration (through creatinine and cystatin C), a standard cholesterol panel, and liver enzymes. An environmental health specialist or clinician can help interpret a biomonitoring result alongside your exposure history and decide whether ongoing monitoring is warranted. There is no validated urine threshold that on its own calls for medical treatment.